Vedanta is playing catch-up with VE303, as a rival microbiome therapy from Seres Therapeutics, called Vowst, has been ...

Following the first-ever FDA approval of a TIL therapy in the U.S., and with regulatory decisions pending in Canada and ...

Returning for its third year, the Donor Selection & Cell Source Summit is the only industry-dedicated forum focused ...

Improved patient outcomes and safety: Ultimately, smarter learning powered by AI should lead to better care. More ...